Immune thrombocytopenia (ITP): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 2
• BCMA 1
• CD22 1
• G6PD 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  NCT05070845· Pfizer· Updated 16 Oct 2026

  “The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

  NCT07039422· Novartis Pharmaceuticals· Updated 15 Oct 2026

  “The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.”Registry text, quoted unchanged. Source

• Terminated

  A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

  NCT06943937· China Immunotech (Beijing) Biotechnology Co., Ltd.· Updated 14 Oct 2026

  “Sponsor decision to discontinue; the study is no longer being pursued due to sponsor strategic reprioritization and resource allocation. The decision was not based on safety concerns. Enrolled participants will complete safety follow-up per protocol.”Registry text, quoted unchanged. Source

• Withdrawn

  Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia

  NCT06813157· Guangzhou Bio-gene Technology Co., Ltd· Updated 28 May 2026

  “Due to corporate strategic adjustment.”Registry text, quoted unchanged. Source

• Terminated

  Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

  NCT05086744· Novartis Pharmaceuticals· Updated 16 Oct 2025

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

  NCT06291415· Hutchmed· Updated 16 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

  NCT06176235· Peking University People's Hospital· Updated 11 Aug 2025

  “Trial withdrawn due to substantial protocol amendments invalidating the original design. With no participants enrolled, this aligns with WHO-ICTRP guidelines. Recruitment has ceased, and the revised protocol has been re-registered as NCT07065968.”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

  NCT03866798· Octapharma· Updated 24 Sept 2024

  “FDA released Octapharma from the pediatric post marketing requirement.”Registry text, quoted unchanged. Source

• Withdrawn

  Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months

  NCT05046327· Sobi, Inc.· Updated 22 Oct 2021

  “Corporate Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  NCT07007962· Sanofi· Source

• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

  NCT05653349· Novartis Pharmaceuticals· Source

• Azithromycin as an Adjunct to Corticosteroids in Children With Newly Diagnosed Immune Thrombocytopenia

  NCT07928895· Tanta University· Source

• Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

  NCT07216079· Sanofi· Source

• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

  NCT05653219· Novartis Pharmaceuticals· Source

• A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

  NCT07421167· Novartis Pharmaceuticals· Source

• A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06722235· Takeda· Source

• A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Takeda· Source

• Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

  NCT07104565· Incyte Corporation· Source

• A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

  NCT05885555· Novartis Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.